Table 1.
Patient characteristics
| Characteristic | Refractory study |
P | Relapsed study |
Treatment-naive study |
|
|---|---|---|---|---|---|
| Rabbit ATG (n = 27) | Alemtuzumab (n = 27) | Alemtuzumab (n = 25) | Alemtuzumab (n = 16) | ||
| Age, y | 40.1 ± 3.8 | 37.2 ± 4.5 | .63 | 39.9 ± 4.5 | 39.2 ± 6.1 |
| Age < 18 y, % | 11.1 ± 6.2 | 25.9 ± 8.6 | .17 | 12 ± 6.6 | 25.0 ± 11.2 |
| Male sex, % | 59.3 ± 9.6 | 51.9 ± 9.8 | .59 | 44 ± 10.1 | 75.0 ± 11.2 |
| Etiology, % | |||||
| Idiopathic | 100 | 92.6 ± 5.1 | .16 | 100 | 93.8 ± 6.3 |
| Posthepatitis | 0 | 7.4 ± 5.1 | .16 | 0 | 6.2 ± 6.3 |
| Blood counts, × 109/L | |||||
| ARC | 21.267 ± 4.064 | 27.048 ± 4.815 | .36 | 35.852 ± 6.452 | 27.394 ± 5.980 |
| ALC | 1.078 ± 0.053 | 0.956 ± 0.086 | .24 | 1.329 ± 0.126 | 1.676 ± 0.170 |
| ANC | 0.616 ± 0.137 | 0.717 ± 0.149 | .62 | 0.595 ± 0.079 | 0.372 ± 0.065 |
| ANC < 0.2, % | 25.9 ± 8.6 | 11.1 ± 6.2 | .168 | 8.0 ± 5.5 | 31.3 ± 12.0 |
| Platelets | 10.654 ± 1.482 | 14.037 ± 1.722 | .146 | 14.880 ± 1.820 | 9.188 ± 2.118 |
| PNH clone < 1%, % | 56.0 ± 9.7 | 77.7 ± 8.2 | .10 | 64.0 ± 9.8 | 50.0 ± 12.9 |
| PNH clone ≥ 1%, % | 44.0 ± 9.7 | 22.3 ± 8.2 | .10 | 36.0 ± 9.8 | 50.0 ± 12.9 |
P refers to the comparison between rabbit ATG and alemtuzumab in the refractory study.
ARC indicates absolute reticulocyte count; ALC, absolute lymphocyte count; ANC, absolute neutrophil count; and PNH, paroxysmal nocturnal hemoglobinuria.